Background & Aim:
Matrix metalloproteinases 9 (MMP-9) play an essential role in the initiation and progression of cancer. In this study, single nucleotide polymorphisms C / T1562- MMP-9 gene promoter with lung cancer were studied.
A case-control study was conducted. MMP-9 gene polymorphism in 100 patients with lung cancer and 100 controls were genotyped using PCR, RFLP and were analyzed.
The results showed that the frequency of CT genotype in this polymorphism in patients (60%) compared to controls (28%) were higher. (OR=3/69, 95% CI= 2/04-6/69, p=0/0001). In order to calculate the risk of metastasis, metastatic and non-metastatic genotype of this polymorphism in the two groups were compared. (OR= 1, 95% CI= 0/31-1/68, p=0/46). Also for the first time the relationship between polymorphism in cancer patients of different sex groups, sex and smoking showed that genotype distribution in groups, men, women, smokers and nonsmokers with lung cancer compared the control group showed no significant difference. (OR for women= 4/44 , 95% CI= 1/61-12/26, P=0/008, OR for men= 3/31, 95% CI= 1/59-6/92, P=0/002, OR for smokers= 4/45, 95% CI = 1/83-10/82, P= 0/002, ,OR for non-smokers=3/2,95%CI=1/42-7/17,P=0/006).
It seems that the polymorphism -1562 C / T MMP-9 gene increase the risk of lung cancer effect, but no effect on metastasis.